サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1563827

キャリア・スクリーニングの世界市場

Carrier Screening

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
キャリア・スクリーニングの世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

キャリア・スクリーニングの世界市場は2030年までに78億米ドルに到達

2023年に28億米ドルと推定されるキャリア・スクリーニングの世界市場は、2023～2030年の分析期間においてCAGR 15.7%で成長し、2030年には78億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである遺伝性疾患は、CAGR18.8%を記録し、分析期間終了までに30億米ドルに達すると予測されます。嚢胞性線維症セグメントの成長率は、分析期間中CAGR 16.6%と推定されます。

米国市場は7億5,680万米ドルと推定、中国はCAGR21.5％で成長予測

米国のキャリア・スクリーニング市場は、2023年に7億5,680万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは21.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.1%と13.4%と予測されています。欧州では、ドイツがCAGR約12.4%で成長すると予測されています。

世界のキャリア・スクリーニング市場- 主要動向と促進要因のまとめ

なぜキャリア・スクリーニングは現代ヘルスケアにおいて重要なツールなのか？

キャリア・スクリーニングは重要な遺伝子検査プロセスであり、個人やカップルが特定の遺伝性疾患の遺伝子を持っているかどうかを判断するのに役立ちます。このスクリーニングは、子宮蓄膿症、テイ・サックス病、鎌状赤血球貧血などの遺伝性疾患を子供に受け継がせるリスクを、これから親になる人が評価できるようにするもので、生殖計画において重要な役割を果たしています。遺伝的健康に対する認識が高まるにつれ、キャリア・スクリーニングは妊娠前・出産前ケアの礎となり、個人が十分な情報を得た上で生殖に関する決定を下す機会を提供しています。個別化医療と予防医療が勢いを増す時代において、キャリア・スクリーニングは早期発見と積極的な健康管理のための強力なツールを提供し、家族が妊娠前にリスクを軽減することを可能にします。キャリア・スクリーニングの価値は、遺伝子に関する詳細な洞察を提供し、遺伝的な相性を理解するのに役立つことにあります。この情報は、遺伝カウンセリング、遺伝学的検査を伴う体外受精（IVF）のような生殖補助医療技術、あるいは他の生殖戦略など、十分な情報に基づいた選択へとカップルを導くことができます。遺伝子技術が進歩し、スクリーニングで特定できる疾患の数が増えるにつれて、キャリア・スクリーニングはますます主流になりつつあり、より多くの家族が重篤な疾患のトランスミッションを防ぐことができる重要な遺伝子情報にアクセスできるようになっています。

技術の進歩はキャリア・スクリーニングをどのように向上させたか？

技術革新はキャリア・スクリーニングを大幅に改善し、より早く、より手頃な価格で、より包括的にしました。最も革新的な進歩の一つは次世代シーケンサー（NGS）で、複数の遺伝子を同時に解析できるようになり、コストを削減しながらスクリーニングされる疾患の範囲が広がりました。NGSにより、より広範で詳細なキャリア・スクリーニングパネルが利用できるようになり、1回の分析で何百もの遺伝子疾患を検査できるようになった。これにより、キャリア・スクリーニングの精度と範囲が劇的に改善され、カップルが遺伝的リスクを包括的に理解し、家族計画に関して十分な情報に基づいた決定を下せるようになりました。家庭用遺伝子検査キットの台頭もキャリア・スクリーニングへのアクセスに革命をもたらし、個人が自宅でDNAサンプルを採取し、認定ラボに送って分析することを可能にしました。これらのキットの利便性と入手しやすさにより、より多くの人々が、場所に関係なく遺伝子検査を受けることが容易になった。バイオインフォマティクスによる遺伝子データ解析の改善とともに、人工知能（AI）の統合が検査結果の精度をさらに高め、人為的ミスの可能性を減らし、より迅速で信頼性の高い遺伝学的洞察を提供しています。AIが進化し続けるにつれて、キャリア・スクリーニングの検査結果の精度と予測力を向上させ、生殖医療における利用をさらに拡大する上で、AIはさらに重要な役割を果たすと予想されます。

キャリア・スクリーニング市場に影響を与える新たな動向とは？

テクノロジーの進歩とヘルスケアの優先順位の変化により、遺伝子検査への取り組み方が変化しているため、現在いくつかの重要な動向がキャリア・スクリーニング市場を形成しています。重要な動向の一つは、より広範な遺伝子疾患が検査パネルに含まれる、拡大キャリア・スクリーニングへの動きです。従来、キャリア・スクリーニングは限られた疾患に焦点を当てていたが、技術の進歩により、現在では1回の検査で数百の遺伝子疾患を含めることができます。この拡大されたスクリーニングアプローチは、遺伝的リスクをより包括的に把握することができ、個人やヘルスケアプロバイダーがより多くの情報に基づいた意思決定を行うことができるため、人気を集めています。もう一つの新たな動向は、個別化医療へのキャリア・スクリーニングの統合です。ヘルスケアが個別化された治療計画へとシフトする中、遺伝子検査は生殖計画のためだけでなく、遺伝的疾患を発症する前に予防するためにも利用されています。さらに、キャリア・スクリーニングは、民族的背景や家族歴に関係なく、子供を持つことを計画しているすべての人に普遍的なサービスとして推奨されるようになってきています。このようなキャリア・スクリーニング普遍化の動向は、より多くのリスクのあるカップルが早期に特定され、その子孫に重篤な遺伝的疾患が遺伝する可能性を減らすための積極的な対策を講じることができるようにするのに役立っています。キャリア・スクリーニングとともに遺伝カウンセリングの役割が大きくなっていることも注目に値します。キャリア・スクリーニングの結果が複雑化するにつれて、遺伝カウンセラーはそのプロセスに不可欠な存在となりつつあり、個人が結果を解釈し、生殖の健康への影響を理解する手助けをしています。さらに、オンラインポータルや遠隔医療などのデジタルツールの台頭により、個人がキャリア・スクリーニングと遺伝カウンセリングサービスの両方に遠隔からアクセスすることが容易になり、この必要不可欠なヘルスケアサービスの範囲がさらに広がっています。

キャリア・スクリーニング市場成長の要因は？

キャリア・スクリーニング市場の成長は、主に遺伝技術の進歩、遺伝性疾患に対する意識の高まり、ヘルスケアプラクティスの進化に関連するいくつかの要因によってもたらされています。主要な促進要因の一つは、家族計画における遺伝的健康の重要性に対する認識の高まりです。遺伝学が疾病予防に果たす役割をより多くの人々が理解するにつれて、キャリア・スクリーニングに対する需要は著しく増加しています。ヘルスケアプロバイダーや遺伝カウンセラーによる啓蒙活動により、キャリア・スクリーニングは、特に遺伝性疾患を受け継ぐリスクのあるカップルにとって、妊娠前および出産前のケアに不可欠なものとして常態化しています。遺伝子検査技術、特に次世代シーケンシング（NGS）の進歩により、キャリア・スクリーニングのコストと納期が短縮され、より多くの人々が利用できるようになりました。このような技術的向上は、自宅での遺伝子検査キットの利便性と相まって、参入障壁を低くし、より多くの個人が生殖の健康を管理するために積極的に行動することを促しています。さらに、これから親になろうとするすべての人にヘルスケア専門家が推奨するユニバーサルキャリア・スクリーニングの動向は、遺伝子検査サービスを求める人の数を増やすことによって市場を拡大しています。規制や保険適用範囲の改善も市場成長の原動力となっています。現在、多くの国でキャリア・スクリーニングに対する保険償還が行われており、個人にとってより手頃な価格となっています。さらに、キャリア・スクリーニングを日常的な生殖医療サービスの一環として採用するヘルスケアプロバイダーが増えるにつれて、市場は継続的に拡大する態勢が整っています。最後に、個人の遺伝子プロファイルに合わせて医療を行う個別化医療や予防医療の台頭により、キャリア・スクリーニングは将来の世代により健康的な結果をもたらすための重要なツールとして位置づけられています。これらの要因は、遺伝子調査における継続的な技術革新とともに、世界中でキャリア・スクリーニングの継続的な成長と採用を後押ししています。

調査対象企業の例（全42件）

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10911

Global Carrier Screening Market to Reach US$7.8 Billion by 2030

The global market for Carrier Screening estimated at US$2.8 Billion in the year 2023, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2023-2030. Genetic Disorders, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Cystic Fibrosis segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$756.8 Million While China is Forecast to Grow at 21.5% CAGR

The Carrier Screening market in the U.S. is estimated at US$756.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Carrier Screening Market - Key Trends and Drivers Summarized

Why Is Carrier Screening a Vital Tool in Modern Healthcare?

Carrier screening is a critical genetic testing process that helps individuals and couples determine if they carry genes for certain inherited disorders, even if they show no symptoms themselves. This screening plays a vital role in reproductive planning, allowing prospective parents to assess the risk of passing genetic conditions, such as cystic fibrosis, Tay-Sachs disease, and sickle cell anemia, to their children. With increasing awareness of genetic health, carrier screening has become a cornerstone of preconception and prenatal care, offering individuals a chance to make informed reproductive decisions. In an era where personalized medicine and preventive care are gaining momentum, carrier screening offers a powerful tool for early detection and proactive health management, allowing families to mitigate risks before conception. The value of carrier screening lies in the detailed genetic insights it provides, helping people understand their genetic compatibility. This information can guide couples toward informed choices such as genetic counseling, assisted reproductive technologies like in vitro fertilization (IVF) with genetic testing, or other reproductive strategies. As genetic technologies advance and the number of conditions identifiable through screening expands, carrier screening is becoming increasingly mainstream, ensuring that more families have access to crucial genetic information that can prevent the transmission of severe disorders.

How Have Technological Advances Enhanced Carrier Screening?

Technological innovations have significantly improved carrier screening, making it faster, more affordable, and more comprehensive. One of the most transformative advancements is next-generation sequencing (NGS), which allows for the analysis of multiple genes simultaneously, increasing the scope of conditions screened for while reducing costs. With NGS, broader and more detailed carrier screening panels are available, testing for hundreds of genetic conditions in a single analysis. This has dramatically improved the accuracy and scope of carrier screening, ensuring that couples receive a comprehensive understanding of their genetic risks and can make well-informed decisions regarding family planning. The rise of at-home genetic testing kits has also revolutionized access to carrier screening, allowing individuals to collect DNA samples at home and send them to certified labs for analysis. The convenience and accessibility of these kits have made it easier for a larger population to undergo genetic testing, regardless of their location. Along with improvements in genetic data analysis through bioinformatics, the integration of artificial intelligence (AI) is further enhancing the precision of test results, reducing the potential for human error, and offering faster, more reliable genetic insights. As AI continues to evolve, it is expected to play an even more critical role in improving the accuracy and predictive power of carrier screening results, further expanding its use in reproductive health.

What Emerging Trends Are Impacting the Carrier Screening Market?

Several important trends are currently shaping the carrier screening market, as advancements in technology and shifting healthcare priorities drive changes in how genetic testing is approached. One of the key trends is the move toward expanded carrier screening, where a broader range of genetic conditions is included in testing panels. Traditionally, carrier screening focused on a limited set of disorders, but advancements in technology now allow for the inclusion of hundreds of genetic conditions in a single test. This expanded screening approach is gaining popularity as it provides a more comprehensive picture of genetic risks, enabling individuals and healthcare providers to make more informed decisions. Another emerging trend is the integration of carrier screening into personalized medicine. As the healthcare landscape shifts toward individualized treatment plans, genetic testing is being used not only for reproductive planning but also to prevent genetic conditions before they develop. In addition, carrier screening is increasingly being recommended as a universal service for all individuals planning to have children, regardless of ethnic background or family history. This trend toward universal carrier screening is helping to ensure that more at-risk couples are identified early, allowing for proactive measures to be taken to reduce the likelihood of transmitting serious genetic conditions to their offspring. The growing role of genetic counseling alongside carrier screening is also noteworthy. As the complexity of carrier screening results increases, genetic counselors are becoming integral to the process, helping individuals interpret results and understand the implications for their reproductive health. Additionally, the rise of digital tools, such as online portals and telemedicine, is making it easier for individuals to access both carrier screening and genetic counseling services remotely, further expanding the reach of this essential healthcare service.

What Factors Are Behind the Growth of the Carrier Screening Market?

The growth in the carrier screening market is driven by several factors, primarily linked to advances in genetic technologies, increased awareness of genetic disorders, and evolving healthcare practices. One of the key drivers is the growing awareness of the importance of genetic health in family planning. As more people understand the role genetics plays in disease prevention, the demand for carrier screening has increased significantly. Educational efforts from healthcare providers and genetic counselors have helped normalize carrier screening as an essential part of preconception and prenatal care, particularly for couples who are at risk of passing on genetic disorders. Advancements in genetic testing technologies, especially next-generation sequencing (NGS), have reduced the cost and turnaround time for carrier screening, making it more accessible to a broader population. These technological improvements, combined with the convenience of at-home genetic testing kits, have lowered barriers to entry, encouraging more individuals to take proactive steps in managing their reproductive health. Moreover, the trend toward universal carrier screening, recommended by healthcare professionals for all prospective parents, has expanded the market by increasing the number of people seeking genetic testing services. Regulatory and insurance coverage improvements have also fueled market growth. Many countries now offer insurance reimbursement for carrier screening, making it more affordable for individuals. Additionally, as more healthcare providers adopt carrier screening as part of routine reproductive health services, the market is poised for continued expansion. Finally, the rise of personalized and preventive medicine, where healthcare is tailored to individual genetic profiles, is positioning carrier screening as a critical tool for ensuring healthier outcomes for future generations. These factors, along with ongoing innovations in genetic research, are driving the continued growth and adoption of carrier screening across the globe.

Select Competitors (Total 42 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Carrier Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Genetic Disorders Propels Growth in the Carrier Screening Market
    • Advances in Genomic Technologies Drive the Accuracy and Accessibility of Carrier Screening
    • Growing Adoption of Carrier Screening in Preconception and Prenatal Care Strengthens the Business Case for Genetic Testing
    • Technological Innovations in Next-Generation Sequencing (NGS) Accelerate Demand for Comprehensive Carrier Screening
    • Rising Incidence of Inherited Genetic Disorders Spurs Market Growth in Carrier Screening
    • Growing Demand for Personalized Medicine Generates Opportunities for Carrier Screening in Tailored Healthcare
    • Integration of AI and Data Analytics in Genetic Testing Enhances Efficiency and Interpretation of Carrier Screening Results
    • Rising Healthcare Expenditure and Insurance Coverage for Genetic Testing Sustain Growth in Carrier Screening Services
    • Expanding Use of Carrier Screening in Fertility Treatments Drives Demand in Assisted Reproductive Technology (ART)
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Carrier Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Tay-Sachs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Biochemical Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • JAPAN
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • CHINA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • EUROPE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • FRANCE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • GERMANY
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • INDIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030
  • AFRICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2024 & 2030

IV. COMPETITION